|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 September 2001, Vol. 98, No. 6, pp. 1721-1726
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
High remission rate in T-cell prolymphocytic leukemia
with CAMPATH-1H
Claire E. Dearden,
Estella Matutes,
Bruno Cazin,
Geir E. Tjønnfjord,
Antonio Parreira,
Benet Nomdedeu,
Pietro Leoni,
Fiona J. Clark,
Deepti Radia,
Saad M. B. Rassam,
Tony Roques,
Nicolas Ketterer,
Vasantha Brito-Babapulle,
Martin J. S. Dyer, and
Daniel Catovsky
From the Royal Marsden NHS Trust, London, United
Kingdom; Hopital C. Huriez, Lille, France; National Hospital, Oslo,
Norway; Institute of Oncology, Lisbon, Portugal; Hospital Clinic,
Barcelona, Spain; University of Ancona, Italy; Southampton University
Hospital, Southampton, United Kingdom; Greenwich Hospital, London,
United Kingdom; Queen Mary's Hospital, Sidcup, Kent, United Kingdom;
Worthing Hospital, Sussex, United Kingdom; and Centre of Oncology,
Lausanne, Switzerland.
T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant
malignancy with a median survival of 7.5 months. Preliminary results
indicated a high remission induction rate with the human CD52 antibody,
CAMPATH-1H. This study reports results in 39 patients with T-PLL
treated with CAMPATH-1H between March 1993 and May 2000. All but 2 patients had received prior therapy with a variety of agents, including
30 with pentostatin; none achieved complete remission (CR). CAMPATH-1H
(30 mg) was administered intravenously 3 times weekly until maximal
response. The overall response rate was 76% with 60% CR and 16%
partial remission (PR). These responses were durable with a median
disease-free interval of 7 months (range, 4-45 months). Survival was
significantly prolonged in patients achieving CR compared to PR or no
response (NR), including one patient who survived 54 months. Nine
patients remain alive up to 29 months after completing therapy. Seven
patients received high-dose therapy with autologous stem cell support,
3 of whom remain alive in CR 5, 7, and 15 months after autograft. Stem
cell harvests in these patients were uncontaminated with T-PLL cells as
demonstrated by dual-color flow cytometry and polymerase chain reaction. Four patients had allogeneic stem cell transplants, 3 from
siblings and 1 from a matched unrelated donor. Two had nonmyeloablative
conditioning. Three are alive in CR up to 24 months after allograft.
The conclusion is that CAMPATH-1H is an effective therapy in T-PLL,
producing remissions in more than two thirds of patients. The use of
stem cell transplantation to consolidate responses merits further study.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Nowak, E. Le Toriellec, M.-H. Stern, N. Kawamata, T. Akagi, M. J. Dyer, W.-K. Hofmann, S. Ogawa, and H. P. Koeffler
Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy
Haematologica,
April 1, 2009;
94(4):
518 - 527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Le Gouill, N. Milpied, A. Buzyn, R. Peffault De Latour, J.-P. Vernant, M. Mohty, M.-P. Moles, K. Bouabdallah, C.-E. Bulabois, J. Dupuis, et al.
Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
J. Clin. Oncol.,
May 10, 2008;
26(14):
2264 - 2271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Berz and N. J. Freeman
Extreme Hyperlymphocytosis
J. Clin. Oncol.,
February 1, 2008;
26(4):
674 - 675.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Herling, K. A. Patel, M. A. Teitell, M. Konopleva, F. Ravandi, R. Kobayashi, and D. Jones
High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia
Blood,
January 1, 2008;
111(1):
328 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gallamini, F. Zaja, C. Patti, A. Billio, M. R. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, et al.
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Blood,
October 1, 2007;
110(7):
2316 - 2323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Bernengo, P. Quaglino, A. Comessatti, M. Ortoncelli, M. Novelli, F. Lisa, and M. T. Fierro
Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients
Haematologica,
June 1, 2007;
92(6):
784 - 794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Rodig, J. S. Abramson, G. S. Pinkus, S. P. Treon, D. M. Dorfman, H. Y. Dong, M. A. Shipp, and J. L. Kutok
Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H)
Clin. Cancer Res.,
December 1, 2006;
12(23):
7174 - 7179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi and S. O'Brien
Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1660 - 1674.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Mone, S. Puhalla, S. Whitman, R. A. Baiocchi, J. Cruz, T. Vukosavljevic, A. Banks, C. F. Eisenbeis, J. C. Byrd, M. A. Caligiuri, et al.
Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia
Blood,
November 15, 2005;
106(10):
3380 - 3382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Lenihan, A. J. Alencar, D. Yang, R. Kurzrock, M. J. Keating, and M. Duvic
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome
Blood,
August 1, 2004;
104(3):
655 - 658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Enblad, H. Hagberg, M. Erlanson, J. Lundin, A. P. MacDonald, R. Repp, J. Schetelig, G. Seipelt, and A. Osterborg
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
Blood,
April 15, 2004;
103(8):
2920 - 2924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Weidmann, M. Gramatzki, M. Wilhelm, and P. S. Mitrou
Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting
Ann. Onc.,
March 1, 2004;
15(3):
369 - 374.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lundin, H. Hagberg, R. Repp, E. Cavallin-Stahl, S. Freden, G. Juliusson, E. Rosenblad, G. Tjonnfjord, T. Wiklund, and A. Osterborg
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
Blood,
June 1, 2003;
101(11):
4267 - 4272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mavromatis and B. D. Cheson
Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 1, 2003;
21(9):
1874 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-W. Li, D. Tang, K. P. Ahrens, J.-X. She, R. C. Braylan, and L. Yang
All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia
Blood,
March 1, 2003;
101(5):
1977 - 1980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Peipp, H. Kupers, D. Saul, B. Schlierf, J. Greil, S. J. Zunino, M. Gramatzki, and G. H. Fey
A Recombinant CD7-specific Single-Chain Immunotoxin Is a Potent Inducer of Apoptosis in Acute Leukemic T Cells
Cancer Res.,
May 1, 2002;
62(10):
2848 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. T Wu
Alemtuzumab (Campath-1H, Campath1) for the treatment of lymphoid malignancies: chronic lymphocytic leukemia and T-cell prolymphocytic leukemia
Journal of Oncology Pharmacy Practice,
December 1, 2001;
7(4):
133 - 140.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Pekarsky, C. Hallas, and C. M. Croce
Molecular Basis of Mature T-Cell Leukemia
JAMA,
November 14, 2001;
286(18):
2308 - 2314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
